Molecular profiling in HNSCC patients targets potential responsiveness to ICIs

Abstract Immunotherapy is emerging as a valid therapeutic strategy for various cancers although only a subset of patients responding to the therapy. The response to immunotherapy remains low for many cancer types because of poor ability to appropriately classify responding patients. We analyzed TCGA cohort of HNSCC patients in relation to a 26 immune gene set and cell types to define signaling pathways associated with resistance to immune …